Table 1.
Descriptive characteristics of patients with T1HG bladder cancer over 80 years at the time of surgery
| Overall | Non-BCG group | BCG group | p value | ||||
|---|---|---|---|---|---|---|---|
| No. Pts./Median | %/IQR | No. Pts./Median | %/IQR | No. Pts./Median | %/IQR | ||
| Characteristics | |||||||
| Male gender | 50 | 83.3 | 22 | 73.3 | 28 | 86.7 | NS |
| Grade 3 | 50 | 83.3 | 22 | 73.3 | 28 | 93.3 | 0.08 |
| Concomitant CIS | 7 | 11.7 | 1 | 3.3 | 6 | 20 | 0.047 |
| Recurrent tumour | 24 | 40 | 11 | 36.7 | 13 | 43.3 | NS |
| Multiple tumours | 35 | 58.3 | 20 | 66.7 | 15 | 50 | NS |
| More than three tumours | 19 | 31.7 | 9 | 30 | 10 | 33.3 | NS |
| Big tumour ≥ 3 cm | 27 | 45 | 16 | 53.3 | 11 | 36.7 | NS |
| No muscle in TURBT specimen | 9 | 15 | 5 | 16.7 | 4 | 13.3 | NS |
| HG tumour history | 15 | 25 | 9 | 30 | 6 | 20 | NS |
| ReTURBT performance | 43 | 71.7 | 20 | 66.7 | 23 | 76.7 | NS |
| Tumour in reTURBT | 22 | 36.7 | 8 | 40 | 14 | 60.9 | 0.18 |
| HG tumour in reTURBT | 25 | 41.7 | 8 | 25 | 17 | 56.5 | 0.037 |
| Comorbidities | |||||||
| Hypertension | 49 | 81.7 | 26 | 86.7 | 23 | 76.7 | NS |
| Coronary artery disease | 39 | 65 | 15 | 50 | 24 | 80 | 0.014 |
| Myocardial infarction | 12 | 20 | 4 | 13.3 | 8 | 26.7 | NS |
| COPD | 6 | 10 | 3 | 10 | 3 | 10 | NS |
| Diabetes mellitus type 2 | 17 | 28.3 | 10 | 33.3 | 7 | 23.3 | NS |
| Dementia | 2 | 3.3 | 2 | 6.7 | 0 | 0 | 0.15 |
| History of other cancer | 11 | 18.3 | 2 | 6.7 | 9 | 30 | 0.020 |
| Stroke | 17 | 28.3 | 9 | 30.5 | 8 | 25.4 | NS |
| Atrial fibrillation | 14 | 23.3 | 6 | 20 | 8 | 26.7 | NS |
| Heart failure | 17 | 28.3 | 8 | 26.7 | 9 | 30 | NS |
| UTUC | 3 | 5 | 2 | 6.7 | 1 | 3.3 | NS |
| Other | |||||||
| Age | 85 | 82–89 | 85 | 81–89.5 | 85 | 82.5–88 | NS |
| Charlson comorbidity index | 7 | 6–8 | 7 | 6–8 | 7 | 6–8 | NS |
| ASA | 3 | 3–3 | 3 | 3–3 | 3 | 3–3 | NS |
| Haemoglobin (g/L) | 128 | 116–141.5 | 129.5 | 113–143 | 127 | 119–139 | NS |
| CUETO recurrence score | 8 | 5–10 | 7.5 | 5–10 | 8 | 5–11 | NS |
| CUETO progression score | 9 | 8–10 | 8 | 8–10 | 9 | 8–10 | 0.09 |
| EORTC recurrence score | 8 | 5–9 | 8 | 6–9 | 7 | 5–8 | NS |
| EORTC progression score | 14 | 9.5–15 | 14 | 9–15 | 14 | 11–15 | NS |
| Outcomes | |||||||
| Recurrence | 40 | 66.7 | 24 | 80 | 16 | 53.3 | 0.029 |
| Progression | 24 | 40 | 15 | 50 | 9 | 30 | 0.11 |
| All-cause death | 33 | 55 | 20 | 66.7 | 13 | 43.3 | 0.07 |
| Cancer-specific death | 15 | 25 | 12 | 40 | 3 | 10 | 0.007 |
Comparison between BCG-treated (N = 30) and non-treated groups (N = 30)
CIS carcinoma in situ, HG high-grade, reTURBT restaging transurethral resection of bladder tumour, COPD chronic obstructive pulmonary disease, ASA American Society of Anesthesiologists Score, IQR interquartile range, The bold values denote statistical significance at the p < 0.05 level